Literature DB >> 22243797

Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking.

Jin-Ming Li1, Yuan-Yuan Wang, Mei-Xia Zhao, Cai-Ping Tan, Yi-Qun Li, Xue-Yi Le, Liang-Nian Ji, Zong-Wan Mao.   

Abstract

Co-delivery of siRNA and chemotherapeutic agents has been developed to combat multidrug resistance in cancer therapy. Recently, we developed a series of quantum dots (QDs) functionalized by β-cyclodextrin (β-CD) coupled to amino acids, some of which can be used to facilitate the delivery of siRNA. In this study, two CdSe/ZnSe QDs modified with β-CD coupled to L-Arg or L-His were used to simultaneously deliver doxorubicin (Dox) and siRNA targeting the MDR1 gene to reverse the multidrug resistance of HeLa cells. In this co-delivery system, Dox was firstly encapsulated into the hydrophobic cavities of β-CD, resulting in bypass of P-glycoprotein (P-gp)-mediated drug efflux. After complex formation of the mdr1 siRNA with Dox-loaded QDs via electrostatic interaction, significant down-regulation of mdr1 mRNA levels and P-gp expression was achieved as shown by RT-PCR and Western blotting experiments, respectively. The number of apoptotic HeLa cells after treatment with the complexes substantially exceeded the number of apoptotic cells induced by free Dox only. The intrinsic fluorescence of the QDs provided an approach to track the system by laser confocal microscopy. These multifunctional QDs are promising vehicles for the co-delivery of nucleic acids and chemotherapeutics and for real-time tracking of treatment.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22243797     DOI: 10.1016/j.biomaterials.2011.12.035

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  40 in total

1.  Theranostic Nanoparticles for RNA-Based Cancer Treatment.

Authors:  Richard A Revia; Zachary R Stephen; Miqin Zhang
Journal:  Acc Chem Res       Date:  2019-05-28       Impact factor: 22.384

2.  Carrier-free, self-assembled pure drug nanorods composed of 10-hydroxycamptothecin and chlorin e6 for combinatorial chemo-photodynamic antitumor therapy in vivo.

Authors:  Yan Wen; Wei Zhang; Ningqiang Gong; Yi-Feng Wang; Hong-Bo Guo; Weisheng Guo; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2017-10-05       Impact factor: 7.790

Review 3.  Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.

Authors:  Jing Li; Yan Wang; Yu Zhu; David Oupický
Journal:  J Control Release       Date:  2013-04-25       Impact factor: 9.776

4.  Heparin based nanoparticles for cancer targeting and noninvasive imaging.

Authors:  Md Nurunnabi; Zehedina Khatun; Woo-Choon Moon; Gibaek Lee; Yong-Kyu Lee
Journal:  Quant Imaging Med Surg       Date:  2012-09

5.  Quantum dot-mediated delivery of siRNA to inhibit sphingomyelinase activities in brain-derived cells.

Authors:  Ted Getz; Jingdong Qin; Igor L Medintz; James B Delehanty; Kimihiro Susumu; Philip E Dawson; Glyn Dawson
Journal:  J Neurochem       Date:  2016-10-14       Impact factor: 5.372

6.  Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.

Authors:  Yuling Xiao; Renata Jaskula-Sztul; Alireza Javadi; Wenjin Xu; Jacob Eide; Ajitha Dammalapati; Muthusamy Kunnimalaiyaan; Herbert Chen; Shaoqin Gong
Journal:  Nanoscale       Date:  2012-11-21       Impact factor: 7.790

7.  Versatile fluorescence resonance energy transfer-based mesoporous silica nanoparticles for real-time monitoring of drug release.

Authors:  Jinping Lai; Birju P Shah; Eric Garfunkel; Ki-Bum Lee
Journal:  ACS Nano       Date:  2013-03-11       Impact factor: 15.881

8.  Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance.

Authors:  Mar Creixell; Nicholas A Peppas
Journal:  Nano Today       Date:  2012-08-01       Impact factor: 20.722

9.  Simultaneous cytosolic delivery of a chemotherapeutic and siRNA using nanoparticle-stabilized nanocapsules.

Authors:  Joseph Hardie; Ying Jiang; Emily R Tetrault; Phaedra C Ghazi; Gulen Yesilbag Tonga; Michelle E Farkas; Vincent M Rotello
Journal:  Nanotechnology       Date:  2016-08-09       Impact factor: 3.874

Review 10.  Nanopreparations to overcome multidrug resistance in cancer.

Authors:  Niravkumar R Patel; Bhushan S Pattni; Abraham H Abouzeid; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2013-08-23       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.